Walter J. Urba
0000-0001-8414-3348
Publication & Citation Trends
Publications
0 total
636 Addition of GITR agonist to a dark matter cancer vaccine and anti-PD-1 increases regulatory T cell numbers without appearing to impact therapeutic efficacy
Cited by 0
Semantic Scholar
1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacy OA
Cited by 2
Semantic Scholar
156 Dark immunopeptidome of head and neck squamous cell carcinoma in serial cell lines from a single patient during multimodality treatment time-course OA
Cited by 0
Semantic Scholar
Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trial
Cited by 2
Semantic Scholar
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Cited by 15
Semantic Scholar
680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma OA
Cited by 0
Semantic Scholar
Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
Cited by 0
Semantic Scholar
Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Cited by 5
Semantic Scholar
Research Topics
Immunotherapy and Immune Responses
(164)
Cancer Immunotherapy and Biomarkers
(154)
CAR-T cell therapy research
(94)
Immune Cell Function and Interaction
(62)
Cancer Genomics and Diagnostics
(39)
Affiliations
University of Southern California
Dartmouth–Hitchcock Medical Center
National Institutes of Health
City Of Hope National Medical Center
Loyola University Medical Center